WO2022063205A8 - 芳基甲酰胺类化合物及其制备方法和医药用途 - Google Patents
芳基甲酰胺类化合物及其制备方法和医药用途 Download PDFInfo
- Publication number
- WO2022063205A8 WO2022063205A8 PCT/CN2021/120150 CN2021120150W WO2022063205A8 WO 2022063205 A8 WO2022063205 A8 WO 2022063205A8 CN 2021120150 W CN2021120150 W CN 2021120150W WO 2022063205 A8 WO2022063205 A8 WO 2022063205A8
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- preparation
- compound
- same
- medicinal uses
- formamide compound
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
一类芳基甲酰胺类化合物及其制备方法和医药用途。特别地,涉及通式(I)所示的化合物、其制备方法及含有该化合物的药物组合物,及其作为P2X3受体拮抗剂的用途,和用于治疗和/或预防与P2X3受体活性相关的疾病例如慢性咳嗽、疼痛、子宫内膜异位、膀胱过度活动症等的用途。其中通式(I)中的各取代基的定义与说明书中的定义相同。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202180049562.3A CN115884970A (zh) | 2020-09-24 | 2021-09-24 | 芳基甲酰胺类化合物及其制备方法和医药用途 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011012216.1 | 2020-09-24 | ||
CN202011012216 | 2020-09-24 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2022063205A1 WO2022063205A1 (zh) | 2022-03-31 |
WO2022063205A8 true WO2022063205A8 (zh) | 2023-03-30 |
Family
ID=80844951
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2021/120150 WO2022063205A1 (zh) | 2020-09-24 | 2021-09-24 | 芳基甲酰胺类化合物及其制备方法和医药用途 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN115884970A (zh) |
WO (1) | WO2022063205A1 (zh) |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2367455T3 (es) * | 2006-11-09 | 2011-11-03 | F. Hoffmann-La Roche Ag | Arilamidas sustituidas por tiazol u oxazol. |
US9238647B2 (en) * | 2009-03-23 | 2016-01-19 | Merck Sharp & Dohme Corp. | P2X3 receptor antagonists for treatment of pain |
WO2010111060A1 (en) * | 2009-03-23 | 2010-09-30 | Merck Sharp & Dohme Corp. | P2x3, receptor antagonists for treatment of pain |
JP5540087B2 (ja) * | 2009-06-22 | 2014-07-02 | エフ.ホフマン−ラ ロシュ アーゲー | P2x3および/またはp2x2/3アンタゴニストとしての、新規なインドール、インダゾールおよびベンゾイミダゾールアリールアミド |
AU2014365823B2 (en) * | 2013-12-16 | 2019-05-02 | Abs Development 1, Inc. | P2X3 and/or P2X2/3 compounds and methods |
US10174016B2 (en) * | 2014-12-09 | 2019-01-08 | Beyer Aktiengesellschaft | 1,3-thiazol-2-yl substituted benzamides |
EP3976179A1 (en) * | 2019-05-31 | 2022-04-06 | Chiesi Farmaceutici S.p.A. | Amino quinazoline derivatives as p2x3 inhibitors |
EP3757103A1 (en) * | 2019-06-27 | 2020-12-30 | Bayer AG | Analogues of 3-(5-methyl-1,3-thiazol-2-yl)-n-{(1r)-1-[2-(trifluoro-methyl)pyrimidin-5-yl]ethyl}benzamide for the treatment of neurogenic diseases |
CR20220126A (es) * | 2019-09-25 | 2022-06-07 | Pfizer | Moduladores de sting (estimulador de genes de interferón) |
-
2021
- 2021-09-24 WO PCT/CN2021/120150 patent/WO2022063205A1/zh active Application Filing
- 2021-09-24 CN CN202180049562.3A patent/CN115884970A/zh active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2022063205A1 (zh) | 2022-03-31 |
CN115884970A (zh) | 2023-03-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12020551870A1 (en) | Tetracyclic heteroaryl compounds | |
MX2021006421A (es) | Anilidas de aminoácidos como moduladores de moléculas pequeñas de interleucinas-17 (il-17). | |
CR20220363A (es) | Compuestos tricíclicos sustituidos | |
BR112021024674A2 (pt) | Derivado heterocíclico de nitrogênio com cinco membros de pirimidina, método de preparação do mesmo e uso farmacêutico do mesmo | |
GEP20227433B (en) | 2-amino-pyridine or 2-amino-pyrimidine derivatives as cyclin dependent kinase inhibitors | |
MX2019010354A (es) | Derivado de heteroaril[4,3-c]pirimidina-5-amina, metodo de preparacion del mismo y usos medicos del mismo. | |
MX2021006283A (es) | Derivados heteroaromáticos para uso como regulador, método de preparación de los mismos y uso de los mismos. | |
EA201992126A1 (ru) | Ингибиторы jak, содержащие 4-членный гетероциклический амид | |
MX2020009657A (es) | Inhibidores de canal de potencial de receptor transitorio de oxadiazol. | |
GEP20146125B (en) | Aminopyrimidines as syk inhibitors | |
EA200970611A1 (ru) | Замещенные пиразолохиназолиновые производные, способ их получения и их применение в качестве ингибиторов киназы | |
TN2019000204A1 (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
DK1723138T3 (da) | Substituerede benzimidazoler og deres anvendelse til at inducere apoptose | |
SA520411787B1 (ar) | مشتقات بنزيميدازول واستخداماتها | |
MX2021011823A (es) | Derivado pirroloheterociclico, metodo de preparacion del mismo y su aplicacion en medicina. | |
MX2023003264A (es) | Inhibidores de cdk y su uso como productos fármaceuticos. | |
MX2021003686A (es) | Medicamento para el tratamiento de la tos cronica. | |
EP4342473A3 (en) | Compounds useful in hiv therapy | |
TN2021000025A1 (en) | Novel heterocyclic amine derivative and pharmaceutical composition comprising same | |
BR112019003320A2 (pt) | compostos de heteroaril carboxamida como inibidores de ripk2 | |
MX2023007265A (es) | Inhibidores de cdk y su uso como productos farmacéuticos. | |
WO2021011713A8 (en) | Imidazopyrimidines as eed inhibitors and the use thereof | |
EA202090959A1 (ru) | Аминзамещенные гетероциклические соединения в качестве ингибиторов ehmt2, их соли и способы их синтеза | |
MX2023003846A (es) | Compuesto de bifenilo como inmunomodulador, metodo de preparacion del mismo y aplicacion del mismo. | |
MX2022012998A (es) | Procedimiento para la preparacion de (3s)-3-(4-cloro-3-{[(2s,3r)-2 -(4-clorofenil)-4,4,4-trifluor-3-metilbutanoil]amino}fenil)-3-aci do ciclo-propilpropanoico y su forma cristalina para uso como principio activo farmaceutico. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21871574 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 21871574 Country of ref document: EP Kind code of ref document: A1 |